Interestingly, copper chelating agents could silence CTR1 and downregulate the phosphorylation of AKT/mTOR molecules after reducing copper concentrations, thus inhibiting PCA progression and improving the anticancer effect of rapamycin on PCA.79, 80. Here, MTOR is linked to posterior cortical atrophy.